First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
Jun 1, 2026 - By Erin Post NEW — Additional Data on Daraxonrasib Released: “Significant Advances” for Pancreatic Cancer Treatment Daraxonrasib is poised to become the new standard of care for previously treated metastatic pancreatic cancer after detailed results from a Phase III clinical trial were released at the American Society of Clinical Oncology (ASCO)
Pancreatic Cancer Action Network1mo ago 
